Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a move that could in the short term severely impair the reputation of Hyderabad-based vaccines maker Shantha Biotechnics, now part of Sanofi-Aventis, the World Health Organization has delisted its popular pentavalent vaccine Shan5, which is used by scores of nations as part of their national immunization programs for the prevention against deadly diseases like diphtheria, tetanus, hepatitis B and Hib
Advertisement

Related Content

No Cease-Fire: India Seeks $190 Million Tax From Sanofi’s Shantha Deal
Off The WHO Hook, Sanofi CEO Viehbacher Plans To Take Shantha's Vaccines To The World
WHO Delists Panacea Biotec's Combination Vaccines From Pre-qualified List; Move Comes A Year After Action Against Sanofi's Shantha Unit
Is Sanofi Planning High-Level Changes At India's Vaccines Unit Shantha? A Leading Biocon Scientist Joins Shantha
Are Biosimilars The Next Big Opportunity In India?
Need For A Vaccines Unit In India Pushes GSK Closer To Align With India's Biological E; Is A Buyout Imminent ?
Sanofi-Aventis Emerging Markets Sales Exceed U.S., Europe: Emerging Markets Earnings Round Up (Part 2)
Sanofi Pasteur's India Arm Shantha Biotech Bags WHO Supply Contract For Pentavalent Vaccines
Sanofi Pasteur's India Arm Shantha Biotech Bags WHO Supply Contract For Pentavalent Vaccines
Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans
Advertisement
UsernamePublicRestriction

Register

SC075781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel